

Atezolizumab  
Essential medicine status  
General description

INN  
Atezolizumab  
ATC codes  
[L01XC18](#) [L01FF05](#)  
Medicine type  
Biological agent  
EML status history

Application rejected in 2019 ([TRS 1021](#)) for [Other specified malignant neoplasms of bronchus or lung](#)  
Added in 2025 ([TRS 1064](#)) for [Other specified malignant neoplasms of bronchus or lung](#)  
Application rejected in 2025 ([TRS 1064](#)) for [Adenocarcinoma of stomach](#)  
Application rejected in 2025 ([TRS 1064](#)) for [Hepatocellular carcinoma of liver](#)  
Therapeutic equivalent for  
[pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)  
[pembrolizumab](#) for [Adenocarcinoma of stomach](#)

Wikipedia  
[Atezolizumab](#)  
DrugBank  
[Atezolizumab](#)

Recommendations  
Section  
Immunomodulators

- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications  
[Other specified malignant neoplasms of bronchus or lung](#) [Hepatocellular carcinoma of liver](#)